Montelunio (Montelukast)

Montelukast, the active ingredient in Montelunio, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It works by blocking cysteinyl leukotriene receptors, thereby reducing bronchoconstriction and inflammation associated with asthma, alleviating nasal symptoms in allergic rhinitis, and preventing exercise‑induced bronchoconstriction in both adult and pediatric patients. The formulation complies with EU regulatory standards and is intended for prescription use under medical supervision.

GNH USA supplies Montelunio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelunio (montelukast) acts on the leukotriene pathway to manage several respiratory conditions.

- Asthma: Improves control of chronic airway inflammation and reduces frequency of wheezing episodes. - Allergic rhinitis: Relieves nasal congestion, sneezing and itchy eyes caused by seasonal allergens. - Exercise‑induced bronchoconstriction: Prevents airway narrowing triggered by physical activity, allowing better exercise tolerance.

Montelunio may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity, often transient and resolves without treatment. - Abdominal pain: occasional stomach discomfort, may be accompanied by nausea. - Cough: transient dry cough, usually resolves with continued therapy. - Diarrhea: loose stools, generally mild and self‑limiting.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, depression, suicidal thoughts or behavior, requiring immediate medical attention. - Allergic reactions: hives, swelling of face or throat, and rare anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement, a medical emergency.

When prescribing Montelunio, several precautions and warnings should be considered. - Pregnancy: Category B, use only if benefits outweigh potential risks. - Breastfeeding: Small amounts excreted in milk; monitor infant for adverse effects. - Hepatic impairment: Use with caution; dose adjustment may be required. - Concomitant asthma therapy: Do not substitute for rescue inhalers; maintain short‑acting bronchodilator availability. - Neuropsychiatric monitoring: Observe patients for mood changes, depression or suicidal ideation. - Store at ambient temperature: Keep below 25°C, in original packaging, protected from moisture and light.

Montelunio can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce montelukast plasma levels. - Ritonavir or other potent CYP3A4 inhibitors: can increase exposure, raising risk of adverse effects.

Moderate Interactions (Monitor Closely): - Phenobarbital: may lower effectiveness, requiring clinical monitoring. - Fluconazole: modest increase in montelukast levels, watch for side effects. - Warfarin: potential alteration of anticoagulant effect, monitor INR.